117 related articles for article (PubMed ID: 22652255)
1. C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Matsuoka H; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Higuchi T; Murakata M; Morikawa K; Shimma N; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
Bioorg Med Chem; 2012 Jul; 20(13):4117-27. PubMed ID: 22652255
[TBL] [Abstract][Full Text] [Related]
2. 5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Matsuoka H; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Higuchi T; Murakata M; Kobayashi T; Morikawa K; Shimma N; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
Bioorg Med Chem; 2011 Sep; 19(18):5334-41. PubMed ID: 21873071
[TBL] [Abstract][Full Text] [Related]
3. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
4. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
7. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
[TBL] [Abstract][Full Text] [Related]
8. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
11. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
13. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
14. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
15. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
16. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
17. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
[TBL] [Abstract][Full Text] [Related]
19. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.
Park EJ; Kong Y; Lee JS; Lee SH; Lee J
Bioorg Med Chem Lett; 2011 Jan; 21(2):742-6. PubMed ID: 21193308
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
